Replies to post #1123 on Vascular Biogenics Ltd (VBLT)

[davidal66]

I think you're right. At the end of the day, if VB111/Avastin shows a 30 day benefit in prolonging life in patients with no options, it will be approved(especially under current FDA stewardship). If VB111 also shows a tail of longer term survivors... i.e. over 18 months, this will strengthen their case. If the survival benefit is less than a month, probably not. The central issue is if the trial shows a survival benefit for patients who received VB111. Fingers crossed for VB111.